Frontal fibrosing alopecia: warning signs, diagnosis and which treatments are considered

Frontal fibrosing alopecia is a primary scarring alopecia, usually regarded as a clinical variant of lichen planopilaris. It typically appears as a band-like recession of the frontotemporal hairline, often with loss of the eyebrows, and it can also affect the eyelashes and facial and body hair. Recognising it matters because, as a scarring condition, the damage to the follicle can be irreversible and the hair loss can become permanent if it is not brought under control.

What frontal fibrosing alopecia is and why it is a concern

FFA is an inflammatory disease of the hair follicle. It belongs to the primary scarring alopecias and is generally considered a clinical variant of lichen planopilaris. That changes the conversation considerably: this is not simply hair falling out, but inflammation that can progressively destroy follicles and leave permanent loss.

It should also not be confused with far more common forms of hair loss. It is not the same as androgenetic alopecia and how it progresses, nor alopecia areata and how it differs from ordinary hair loss, nor telogen effluvium, when shedding starts suddenly and usually reverses. The differential diagnosis includes precisely these conditions, along with other scarring alopecias.

As for the cause, the literature considers hypotheses such as a hereditary predisposition or external exposures and personal care products, but there is no conclusive confirmation of a direct causal link. Nor have studies on diet identified any foods that slow FFA down or make the hair grow back.

Warning signs that point to FFA

The most telling pattern is a progressive, band-like recession of the frontal or frontotemporal hairline. It is very often accompanied by loss of the eyebrows, and there may also be loss of eyelashes or facial or body hair. Some people also notice itching, burning, pain or trichodynia.

On examination there may be redness and scaling around the follicles, facial papules and skin that looks shiny or atrophic in the affected area. In the Mayo Clinic series of 148 women, 60.1% had eyebrow loss, 67.6% itching and 27.7% trichodynia. In the multicentre series of 355 patients, loss of eyelashes, facial papules and involvement of body hair were associated with more severe forms.

One combination is particularly important: a progressively receding frontal hairline together with eyebrow loss. That situation deserves assessment because it may be a scarring alopecia.

How it is diagnosed

FFA is diagnosed mainly on clinical grounds. Diagnosis relies on a dermatological examination and trichoscopy, and a biopsy is used when there is doubt or when histological confirmation is needed. If that confirmation is required, a scalp biopsy is the definitive standard.

Trichoscopy may show perifollicular redness, perifollicular scaling, an absence of vellus hairs and, in some cases, the so-called lonely hair sign. These findings help distinguish an inflammatory scarring alopecia from other types of hair loss.

Which treatments are considered today

In Spain, the medicines used in FFA and mentioned below are not specifically authorised for this indication; when they are used in FFA, it is off-label use. FFA is an inflammatory disease of the follicle, and the realistic aim of treatment is to halt progression, reduce symptoms and inflammation and try to achieve some regrowth in selected cases, bearing in mind that recovery is usually limited. The AAD also notes that treating early can help stop it advancing further and preserve the remaining hair.

The international SOFFIA 2024 consensus recommends considering treatment from the point of diagnosis, often as a combination. Among the options experts use most often are 5-alpha-reductase inhibitors, followed by hydroxychloroquine. For the eyebrows they favour intralesional corticosteroids, and for facial papules they place low-dose oral isotretinoin among the preferred options. Follow-up is usually long-term and frequently requires a combination of therapies.

The AAD notes that a dermatologist may inject corticosteroids into the scalp and eyebrows; in one study, 10 of 11 patients with eyebrow loss had some regrowth, although they were also receiving other treatments. It also summarises a small study in which adding finasteride or dutasteride prevented further hair loss in every patient, and almost half had some regrowth. In another small study of 54 patients treated with hydroxychloroquine, 8 had some regrowth, 32 stabilised and 12 got worse.

Not everything used for other types of alopecia works in the same way here. The AAD states that minoxidil on its own is unlikely to stop FFA from getting worse. If you want to understand its role in other forms of hair loss, it may help to read oral versus topical minoxidil and what the head-to-head trials show and low-dose oral minoxidil and a map of its real side effects.

SOFFIA 2024 also discusses other systemic treatments such as ciclosporin, methotrexate or mycophenolate, with varying levels of agreement. At the same time, it is wise to keep expectations realistic: in the Mayo Clinic series of 148 women, only 26.3% achieved stabilisation of the disease, often with combination therapy.

What is known about safety and authorisation in Spain

In Spain, finasteride 1 mg is authorised in CIMA as Propecia 1 mg for male androgenetic alopecia, not specifically for FFA. Dutasteride 0.5 mg is authorised for benign prostatic hyperplasia, not for FFA. Hydroxychloroquine is available in Spain but is not specifically authorised for FFA. Isotretinoin is authorised for severe acne under expert medical supervision, and acitretin for certain severe skin conditions or psoriasis, not for FFA.

There are also safety issues that are far from minor. In 2025 the EMA announced measures to minimise the risk of suicidal thoughts with finasteride and dutasteride, and suicidal thoughts were confirmed as a side effect of oral finasteride. The AAD also states that finasteride and dutasteride are not safe during pregnancy. Systemic retinoids such as isotretinoin and acitretin carry significant risks, particularly teratogenicity.

What to take away

The key idea is simple: frontal fibrosing alopecia is not ordinary hair loss but an inflammatory scarring alopecia, in which spotting the warning signs in time can make the difference between continuing to lose hair and trying to stabilise the process. In Spain today, care involves a prior medical assessment, a prescription where appropriate from a registered doctor and ongoing follow-up as part of medical hair loss treatment. If you want to take the first step, you can check in a few minutes whether this treatment suits your case.